 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

---
- Cerecor's (CERC) wholly-owned subsidiary, Aevi Genomic Medicine (GNMX) has entered
  into an expanded agreement with Kyowa Kirin (KYKOF), for exclusive worldwide rights
  to...


Cerecor inks CERC-002 licensing deal with Kyowa Kirin, shares up 6%

---
- Aevi Genomic Medicine (NASDAQ:GNMX) and Amgen (NASDAQ:AMGN) are both medical companies,
  but which is the better stock? We will contrast the two businesses based on the
  strength of their analyst recommendations, valuation, risk, profitability, institutional
  ownership, earnings and dividends. Insider ...


Contrasting Aevi Genomic Medicine (NASDAQ:GNMX) & Amgen (NASDAQ:AMGN)

---
- Amgen (NASDAQ:AMGN) and Aevi Genomic Medicine (NASDAQ:GNMX) are both companies,
  but which is the superior business? We will contrast the two businesses based on
  the strength of their institutional ownership, analyst recommendations, earnings,
  valuation, profitability, risk and dividends. Earnings ...


Head-To-Head Comparison: Amgen (NASDAQ:AMGN) & Aevi Genomic Medicine (NASDAQ:GNMX)

---
- Maryland biopharmaceutical company Cerecor has completed its acquisition of Wayne-based
  Aevi Genomic Medicine Inc. in a transaction involving two companies both focused
  on developing new therapies for rare pediatric diseases. The all-stock deal, first
  disclosed in December, carries a value up to $22.1 million.


Cerecor completes acquisition of Pennsylvania biopharma

Done deal: Maryland biopharm firm completes acquisition of Aevi Genomic Medicine

---
- "-Cerecor Emerges as a Leading Biopharmaceutical Company in Rare Pediatric and Orphan
  Diseases-Mike Cola Named Chief Executive Officer and Dr. Garry Neil Named Chief
  Medical Officer ROCKVILLE, Md., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:
  CERC), a biopharmaceutical company focused on ..."


Cerecor and Aevi Genomic Medicine Complete Merger

---
- 'Cerecor to Acquire Aevi Genomic Medicine Cerecor to Acquire Aevi Genomic Medicine
  PR Newswire PHILADELPHIA, Dec. 5, 2019 PHILADELPHIA, Dec. 5, 2019 /PRNewswire/ --
  Aevi Genomic Medicine, Inc. (''Aevi'') (Nasdaq: GNMX) today announced that it entered
  into a definitive merger agreement with ...'


Cerecor to Acquire Aevi Genomic Medicine

---
- "-Expands Clinical-stage Pipeline, Further Positioning Cerecor as a Leader in Rare
  and Orphan Diseases-Enhances Leadership Team with the Addition of Chief Executive
  Officer and Chief Medical Officer-Strategic Alternatives Being Explored for Neurological
  Assets and Millipred ROCKVILLE, Md., Dec. 05, ..."


---
- Aevi Genomic Medicine Inc (NASDAQ:GNMX) has earned a consensus broker rating score
  of 3.00 (Hold) from the one brokers that provide coverage for the company, Zacks
  Investment Research reports. One investment analyst has rated the stock with a hold
  rating. Analysts have set a 1 year consensus price ...


Zacks: Brokerages Set $0.50 Price Target for Aevi Genomic Medicine Inc (NASDAQ:GNMX)

Aevi Genomic Medicine, Inc. is a clinical stage biopharmaceutical company, which engages in finding treatments for rare and orphan diseases. Its research and development efforts leverage an internal genomics platform and an ongoing collaboration with the Center for Applied Genomics (CAG) at The Children's Hospital of Philadelphia (CHOP). The company was founded by Andrew Leonard Pearlman on January 27, 2000 and is headquartered in Wayne, PA.

Market Cap	$0.00
52-Wk High	$0.00
52-Wk Low	$0.00

GNMX Aevi Genomic Medicine

About

Feed

News

Fundamentals